Fenretinide metabolism in humans and mice: Utilizing pharmacological modulation of its metabolic pathway to increase systemic exposure

British Journal of Pharmacology

Volumn 163, Issue 6, 2011, Pages 1263-1275

  Cooper, Jason P ^a   Hwang, Kyunghwa ^a   Singh, Hardeep ^a   Wang, Dong ^a   Reynolds, C Patrick ^a,b,c   Curley Jr , Robert W ^d   Williams, Simon C ^a   Maurer, Barry J ^a,b,c   Kang, Min H ^a,b,c  

^a Cancer Center   (United States)

^b Department of Pharmacology and Neuroscience ^*  (United States)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

fenretinide; ketoconazole; metabolism; paediatric cancers

Indexed keywords

4 OXO N (4 HYDROXYPHENYL)RETINAMIDE; CYTOCHROME P450 3A4; DRUG METABOLITE; FENRETINIDE; KETOCONAZOLE; N (4 METHOXYPHENYL)RETINAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG OXIDATION; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER MICROSOME; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPECIES DIFFERENCE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE; DRUG INTERACTIONS; FENRETINIDE; HUMANS; KETOCONAZOLE; MICE; MICE, INBRED NOD; MICE, NUDE; MICE, SCID; MICROSOMES, LIVER; MOLECULAR STRUCTURE;

EID: 79959722919     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01310.x     Document Type: Article

References (47)

1. Appierto V, Cavadini E, Pergolizzi R, Cleris L, Lotan R, Canevari S, et al,. (2001). Decrease in drug accumulation and in tumour aggressiveness marker expression in a fenretinide-induced resistant ovarian tumour cell line. Br J Cancer 84: 1528-1534. (Pubitemid 32579346)
2. Cheng EH, Wei MC, Weiler S, Flavell RA, Mak TW, Lindsten T, et al,. (2001). BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell 8: 705-711. (Pubitemid 32946946)
3. Chiesa F, Tradati N, Grigolato R, Boracchi P, Biganzoli E, Crose N, et al,. (2005). Randomized trial of fenretinide (4-HPR) to prevent recurrences, new localizations and carcinomas in patients operated on for oral leukoplakia: long-term results. Int J Cancer 115: 625-629. (Pubitemid 40656722)
4. Chithalen JV, Luu L, Petkovich M, Jones G, (2002). HPLC-MS/MS analysis of the products generated from all-trans-retinoic acid using recombinant human CYP26A. J Lipid Res 43: 1133-1142. (Pubitemid 34760885)
5. Delia D, Aiello A, Lombardi L, Pelicci PG, Grignani F, Grignani F, et al,. (1993). N-(4-hydroxyphenyl)retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. Cancer Res 53: 6036-6041.
6. Formelli F, Cleris L, (1993). Synthetic retinoid fenretinide is effective against a human ovarian carcinoma xenograft and potentiates cisplatin activity. Cancer Res 53: 5374-5376. (Pubitemid 23342152)
7. Formelli F, Cavadini E, Luksch R, Garaventa A, Villani M, Appierto V, et al,. (2008). Pharmacokinetics of oral fenretinide in neuroblastoma patients: indications for optimal dose and dosing schedule also with respect to the active metabolite 4-oxo-fenretinide. Cancer Chemother Pharmacol 62: 655-665.
8. Garaventa A, Luksch R, Lo Piccolo MS, Cavadini E, Montaldo PG, Pizzitola MR, et al,. (2003). Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. Clin Cancer Res 9: 2032-2039. (Pubitemid 36687622)
9. Garcia AA, Morgan R, McNamara M, Scudder S, Tsao-Wei D, Groshen S, et al,. (2004). Phase II trial of fenretinide (4-HPR) in recurrent ovarian and primary peritoneal carcinoma: a California cancer consortium trial. J Clin Oncol 22: (abstr 5056).
10. Hultin TA, May CM, Moon RC, (1986). N-(4-hydroxyphenyl)-all-trans- retinamide pharmacokinetics in female rats and mice. Drug Metab Dispos 14: 714-717. (Pubitemid 17202412)
11. Illingworth N, Boddy A, Daly A, Veal G, (2011). Characterization of the metabolism of fenretinide by human liver microsomes, cytochrome P450 enzymes and UDP-glucuronosyltransferases. Br J Pharmacol 162: 989-999.
12. Jasti BR, LoRousso P, Parchment RE, Wozniak AJ, Flaherty LE, Shields LF, et al,. (2001). Phase I clinical trial of fenretinide (NSC374551) in advanced solid tumors. Proc Am Soc Clin Oncol: abstr 485.
13. Jia L, Liu X, (2007). The conduct of drug metabolism studies considered good practice (II): in vitro experiments. Curr Drug Metab 8: 822-829. (Pubitemid 350238912)
14. Kalemkerian GP, Slusher R, Ramalingam S, Gadgeel S, Mabry M, (1995). Growth inhibition and induction of apoptosis by fenretinide in small-cell lung cancer cell lines. JNCI J Natl Cancer Inst 87: 1674-1680.
15. Kang MH, Wan Z, Kang Y, Sposto R, Reynolds CP, (2008). Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation. J Natl Cancer Inst 100: 580-595.
16. Lee JS, Newman RA, Lippman SM, Fossella FV, Calayag M, Raber MN, et al,. (1995). Phase I evaluation of all-trans retinoic acid with and without ketoconazole in adults with solid tumors. J Clin Oncol 13: 1501-1508.
17. Liu X, Maurer B, Frgala T, Page J, Noker P, Fulton R, et al,. (2007). Preclinical toxicology and pharmacokinetics of intravenous lipid emulsion fenretinide. Mol Cancer Ther 12: Pt 2: abstr C159.
18. Marachelian A, Kang MH, Hwang KH, Villablanca JG, Groshen S, Mathay KK, et al,. (2009). Phase I study of fenretinide (4-HPR) oral powder in patients with recurrent or resistant neuroblastoma: New Approaches to Neuroblastoma Therapy (NANT) Consortium trial. J Clin Oncol 27: 15s (Suppl; abstr 10009).
19. Mariotti A, Marcora E, Bunone G, Costa A, Veronesi U, Pierotti MA, et al,. (1994). N-(4-hydroxyphenyl)retinamide: a potent inducer of apoptosis in human neuroblastoma cells. J Natl Cancer Inst 86: 1245-1247. (Pubitemid 24253701)
20. Masters JR, Thomson JA, ly-Burns B, Reid YA, Dirks WG, Packer P, et al,. (2001). Short tandem repeat profiling provides an international reference standard for human cell lines. Proc Natl Acad Sci USA 98: 8012-8017. (Pubitemid 32642678)
21. Maurer BJ, Kalous O, Yesair DW, Wu X, Janeba J, Maldonado V, et al,. (2007). Improved oral delivery of N-(4-hydroxyphenyl)retinamide with a novel LYM-X-SORB organized lipid complex. Clin Cancer Res 13: 3079-3086. (Pubitemid 46849585)
22. Mehta RR, Hawthorne ME, Graves JM, Mehta RG, (1998). Metabolism of N-[4-hydroxyphenyl]retinamide (4-HPR) to N-[4-methoxyphenyl]retinamide (4-MPR) may serve as a biomarker for its efficacy against human breast cancer and melanoma cells. Eur J Cancer 34: 902-907.
23. Mohrbacher A, Gutierrez M, Murgo AJ, Kummar S, Reynolds CP, Maurer BJ, et al,. (2007). Phase I trial of fenretinide (4-HPR) intravenous emulsion for hematologic malignancies. J Clin Oncol 25: 18s (suppl; abstr 2851).
24. Muindi JR, Young CW, Warrell RP Jr, (1994). Clinical pharmacology of all-trans retinoic acid. Leukemia 8: 1807-1812. (Pubitemid 24363052)
25. Nivoix Y, Leveque D, Herbrecht R, Koffel JC, Beretz L, Ubeaud-Sequier G, (2008). The enzymatic basis of drug-drug interactions with systemic triazole antifungals. Clin Pharmacokinet 47: 779-792.
26. O'Donnell PH, Guo WX, Reynolds CP, Maurer BJ, (2002). N-(4-hydroxyphenyl)retinamide increases ceramide and is cytotoxic to acute lymphoblastic leukemia cell lines, but not to non-malignant lymphocytes. Leukemia 16: 902-910. (Pubitemid 34537564)
27. Oridate N, Lotan D, Xu XC, Hong WK, Lotan R, (1996). Differential induction of apoptosis by all-trans-retinoic acid and N-(4-hydroxyphenyl) retinamide in human head and neck squamous cell carcinoma cell lines. Clin Cancer Res 2: 855-863. (Pubitemid 26168938)
28. Ozpolat B, Mehta K, Tari AM, Lopez-Berestein G, (2002). all-trans-Retinoic acid-induced expression and regulation of retinoic acid 4-hydroxylase (CYP26) in human promyelocytic leukemia. Am J Hematol 70: 39-47.
29. Ozpolat B, Tari AM, Mehta K, Lopez-Berestein G, (2004). Nuclear retinoid receptors are involved in N-(4-hydroxyphenyl) retinamide (Fenretinide)-induced gene expression and growth inhibition in HL-60 acute myeloid leukemia cells. Leuk Lymphoma 45: 979-985. (Pubitemid 38444675)
30. Puduvalli VK, Yung WK, Hess KR, Kuhn JG, Groves MD, Levin VA, et al,. (2004). Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: a North American Brain Tumor Consortium study. J Clin Oncol 22: 4282-4289. (Pubitemid 41185149)
31. Reagan-Shaw S, Nihal M, Ahmad N, (2008). Dose translation from animal to human studies revisited. FASEB J 22: 659-661. (Pubitemid 351348146)
32. Reynolds CP, Frgala T, Tsao-Wei D, Groshen S, Morgan R, McNamara M, et al,. (2007). High plasma levels of fenretinide (4-HPR) were associated with improved outcome in a phase II study of recurrent ovarian cancer: a study by the California Cancer Consortium. J Clin Oncol 25: 18s (suppl; abstr 5555).
33. Sabichi AL, Modiano MR, Lee JJ, Peng YM, Xu MJ, Villar H, et al,. (2003). Breast tissue accumulation of retinamides in a randomized short-term study of fenretinide. Clin Cancer Res 9: 2400-2405. (Pubitemid 36842078)
34. Sabichi AL, Lerner SP, Atkinson EN, Grossman HB, Caraway NP, Dinney CP, et al,. (2008). Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. Clin Cancer Res 14: 224-229. (Pubitemid 351377999)
35. Scheen AJ, (2007). Pharmacokinetic interactions with thiazolidinediones. Clin Pharmacokinet 46: 1-12. (Pubitemid 46089664)
36. Sonneveld E, van den Brink CE, van der Leede BM, Schulkes RK, Petkovich M, van der Burg B, et al,. (1998). Human retinoic acid (RA) 4-hydroxylase (CYP26) is highly specific for all-trans-RA and can be induced through RA receptors in human breast and colon carcinoma cells. Cell Growth Differ 9: 629-637. (Pubitemid 28367252)
37. Thatcher N, (2005). Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366: 1527-1537. (Pubitemid 41540110)
38. Vaishampayan U, Heilbrun LK, Parchment RE, Jain V, Zwiebel J, Boinpally RR, et al,. (2005). Phase II trial of fenretinide in advanced renal carcinoma. Invest New Drugs 23: 179-185. (Pubitemid 40386236)
39. Van Wauwe JP, Coene MC, Goossens J, Van NG, Cools W, Lauwers W, (1988). Ketoconazole inhibits the in vitro and in vivo metabolism of all-trans-retinoic acid. J Pharmacol Exp Ther 245: 718-722.
40. Van Wauwe JP, Coene MC, Goossens J, Cools W, Monbaliu J, (1990). Effects of cytochrome P-450 inhibitors on the in vivo metabolism of all-trans-retinoic acid in rats. J Pharmacol Exp Ther 252: 365-369. (Pubitemid 20067737)
41. Van Wauwe JP, Coene MC, Cools W, Goossens J, Lauwers W, Le JL, et al,. (1994). Liarozole fumarate inhibits the metabolism of 4-keto-all-trans-retinoic acid. Biochem Pharmacol 47: 737-741. (Pubitemid 24094279)
42. Veronesi U, de Palo G, Marubini E, Costa A, Formelli F, Mariani L, et al,. (1999). Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst 91: 1847-1856.
43. Villablanca JG, Krailo MD, Ames MM, Reid JM, Reaman GH, Reynolds CP, (2006). Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709). J Clin Oncol 24: 3423-3430. (Pubitemid 46638899)
44. Villani MG, Appierto V, Cavadini E, Valsecchi M, Sonnino S, Curley RW, et al,. (2004). Identification of the fenretinide metabolite 4-Oxo-fenretinide present in human plasma and formed in human ovarian carcinoma cells through induction of cytochrome P450 26A1. Clin Cancer Res 10: 6265-6275. (Pubitemid 39287535)
45. Villani MG, Appierto V, Cavadini E, Bettiga A, Prinetti A, Clagett-Dame M, et al,. (2006). 4-Oxo-fenretinide, a recently identified fenretinide metabolite, induces marked G2-M cell cycle arrest and apoptosis in fenretinide-sensitive and fenretinide-resistant cell lines. Cancer Res 66: 3238-3247.
46. Vratilova J, Frgala T, Maurer BJ, Patrick RC, (2004). Liquid chromatography method for quantifying N-(4-hydroxyphenyl)retinamide and N-(4-methoxyphenyl)retinamide in tissues. J Chromatogr B Analyt Technol Biomed Life Sci 808: 125-130. (Pubitemid 38952906)
47. William WN Jr, Lee JJ, Lippman SM, Martin JW, Chakravarti N, Tran HT, et al,. (2009). High-dose fenretinide in oral leukoplakia. Cancer Prev Res (Phila) 2: 22-26.